莫西沙星治疗多重或泛耐药鲍曼不动杆菌引起的重症肺炎的方法

Moxifloxacin Treatment of Severe Pneumonia Caused by Multiple or Pan-resistant Acinetobacter Baumannii

目的探讨莫西沙星在多重或泛耐药鲍曼不动杆菌(MDRAB)重症肺炎中的临床治疗效果。方法选择2018年2月—2019年2月收治的85例MDRAB重症肺炎患者,将采用头孢哌酮钠舒巴坦钠进行治疗的43例患者设为对照组,另将莫西沙星联合头孢哌酮钠舒巴坦钠治疗的42例患者设为观察组,对比两组患者的临床疗效、血清指标、不良反应、细菌清除率及再感染率。结果观察组患者的治疗有效率(83.3%)明显高于对照组(62.8%),差异有统计学意义(χ^2=4.543,P=0.033);经过治疗后,观察组患者的PCT、CRP及WBC血清指标水平均明显低于对照组患者,差异有统计学意义(t=9.977,11.442,9.143,P<0.05);此外,治疗后观察组患者的细菌清除率达85.7%,明显高于对照组患者的细菌清除率(65.1%),差异有统计学意义(χ^2=4.846,P=0.028);且观察组患者的再感染率(4.8%)也大大低于对照组患者,差异有统计学意义(χ^2=4.930,P=0.026);两组患者的不良反应发生情况较为一致,差异无统计学意义(χ^2=0.133,P=0.715)。结论莫西沙星在多重或泛耐药鲍曼不动杆菌引起的重症肺炎中具有确切的治疗效果,具有较高的可行性与安全性。

Objective To explore the clinical therapeutic effect of moxifloxacin in severe pneumonia with multiple or pan-resistant Acinetobacter baumannii(MDRAB).Methods 85 patients with severe MDRAB pneumonia admitted from February 2018 to February 2019 were selected,and 43 patients treated with cefoperazone sodium and sulbactam sodium were set as the control group,and moxifloxacin combined with cefoperazone sodium and sulbactam sodium were treated.42 patients were set as the observation group,and the clinical efficacy,serum indexes,adverse reactions,bacterial clearance rate and reinfection rate of the two groups were compared.Results The treatment efficiency of the observation group(83.3%)was significantly higher than that of the control group(62.8%),the difference was statistically significant(χ^2=4.543,P=0.033);after treatment,the PCT,CRP and WBC serum indexes of the observation group were significantly higher compared with the control group,the differences were significant(t=9.977,11.442,9.143,P<0.05);in addition,the bacterial clearance rate of the observation group after treatment reached 85.7%,which is significantly higher than the bacterial clearance rate of the control group(65.1%),with a large difference(χ^2=4.846,P=0.028);and the reinfection rate of the observation group(4.8%),also significantly lower than that of the control group,the difference was statistically significant(χ^2=4.930,P=0.026);the occurrence of adverse reactions in the two groups of patients was more consistent and not statistically significant(χ^2=0.133,P=0.715).Conclusion Moxifloxacin has a definite therapeutic effect in severe pneumonia caused by multiple or pan-resistant Acinetobacter baumannii,with high feasibility and safety.